PDF(Pubmed)
Abstract：
The Cambridge Centre for Myelin Repair One (CCMR-One) trial showed that 6 months of bexarotene reduces visual evoked potential (VEP) latency in people with relapsing-remitting multiple sclerosis (MS). In a single-centre follow-up study of these participants, we re-examined full-field VEP and clinical assessments. Twenty participants (12 bexarotene and 8 placebo) were seen on average 27 months after their trial involvement. In an analysis of all eyes with recordable signal (24 bexarotene and 14 placebo), the adjusted bexarotene-placebo treatment difference in P100 latency was -7.79 (95% confidence interval (CI) = -14.76, -0.82) ms, p = 0.044. We conclude that there were durable improvements in VEP latency, suggesting long-term benefits from exposure to a remyelinating drug.
摘要：
剑桥髓磷脂修复中心（CCMR-One）试验表明，6个月的贝沙罗汀可减少复发缓解型多发性硬化症（MS）患者的视觉诱发电位（VEP）潜伏期。在对这些参与者的单中心随访研究中，我们重新检查了全视野VEP和临床评估.20名参与者（12名贝沙罗汀和8名安慰剂）在参与试验27个月后平均被发现。在对具有可记录信号的所有眼睛的分析中（24个贝沙罗汀和14个安慰剂），P100潜伏期的调整贝沙罗汀-安慰剂治疗差异为-7.79（95％置信区间（CI）=-14.76，-0.82）ms，p=0.044。我们得出的结论是，VEP延迟有了持久的改善，表明暴露于髓鞘再生药物的长期益处。
